A Phase 3 interventional study of Human regular insulin and Insulin lispro in Hyperglycemia, sponsored by Eli Lilly and Company. Terminated at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-13.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing Insulin Glargine in Hyperglycemia — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Hyperglycemia.
Among the 15 studies testing Insulin Glargine in Hyperglycemia, this one is the 13th largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 9th registered.
802 studies on the registry are indexed under Hyperglycemia; 115 are open to participants now.
Browse Hyperglycemia studies →None of the 15 studies testing Insulin Glargine in Hyperglycemia is open now. The open studies under Hyperglycemia, anywhere →
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 71 Hyperglycemia studies recruiting now, 42 (59%) set no upper age limit and 23 (32%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 50 across 622 interventional studies indexed under Hyperglycemia.
Median enrollment 72 across the 15 interventional studies. Of the 12 that completed or were terminated, 9 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 15 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Eli Lilly and Company has 3 studies filed under Hyperglycemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 15 studies testing Insulin Glargine in Hyperglycemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the use of insulin glargine plus insulin lispro to human regular insulin for treatment of hyperglycemia in the hospital setting in patients without known prior history of diabetes.
This study involves a comparison of 2 methods for administering subcutaneous insulin therapy to non-critically ill adult patients with hyperglycemia and without known history of diabetes who are admitted to non-intensive care unit (ICU) general medical hospital services. Basal-bolus therapy, considered the gold standard for glucose control in patients with known diabetes, will be compared with sliding scale insulin, a commonly used method of glucose control (prevailing standard practice) in hospitalized patients. In this study, basal-bolus therapy will consist of once-daily glargine plus lispro 3 to 4 times daily adjusted to achieve pre-meal capillary plasma glucose \<140 milligrams per deciliter (mg/dL) and bedtime capillary plasma glucose \<180 mg/dL for patients who are eating [predose plasma glucose \<140 mg/dL for patients with nil per os (NPO) orders]; sliding scale insulin will be administered using human regular insulin 4 times daily as needed adjusted to achieve predose capillary plasma glucose target \<140 mg/dL in patients who are eating or have NPO orders.
Major Inclusion Criteria:
Major Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Human regular insulin
Drug: Insulin lispro · Drug: Insulin glargine
Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
Also known as: Humulin R, LY041001
Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
Also known as: Humalog, LY275585
Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
Also known as: Lantus
Mean Plasma Glucose (MPG) Throughout Hospital Study Period
Overall MPG is derived as the mean of plasma glucose (PG) readings from Day/Visit 1 to Day/Visit 10.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period
Results are reported as the percentage of total number of capillary plasma glucose measurements within the range of 71 to 179 mg/dL for each treatment arm.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Mean Plasma Glucose (MPG) by Hospital Day
The intent was to report results up to Day 10; however, due to low enrollment, mean and standard deviations are only reported up to Day 7.
Time frame: Day 1 up to day 7 of hospital study period
Percentage of Plasma Glucose Measurements Within Range 71 to 179 mg/dL by Hospital Day
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL Throughout Hospital Study Period
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Percentage of Participants Achieving MPG Within Range 71 to 179 mg/dL and Within the Target of 100 to 179 mg/dL by Hospital Day
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Mean Fasting Plasma Glucose (FPG) by Hospital Day
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Mean FPG Throughout Hospital Study Period
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL Throughout the Hospital Study Period
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout the hospital study period (1 to 10 days post-randomization)
Percentage of Fasting Capillary PG Measurements Within the Range of 71 to 139 mg/dL and Within the Target of 100 to 139 mg/dL by Hospital Day
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL Throughout the Hospital Study Period
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout the hospital study period (1 to 10 days post-randomization)
Percentage of Participants Achieving Mean FPG Range of 71 to 139 mg/dL and Target of 100 to 139 mg/dL by Hospital Day
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Percentage of Capillary PG Measurements >240 mg/dL Throughout the Hospital Study Period
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout the hospital study period (1 to 10 days post-randomization)
Percentage of Capillary PG Measurements >240 mg/dL by Hospital Day
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Total Daily Dose (TDD) of Insulin (Units) Throughout the Hospital Study Period
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout the hospital study period (1 to 10 days post-randomization)
TDD of Insulin (Units/kg) Throughout the Hospital Study Period
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout the hospital study period (1 to 10 days post-randomization)
TDD of Insulin (Units) by Hospital Day
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
TDD of Insulin (Units/kg) by Hospital Day
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Length of Hospital Stay Post-randomization Throughout the Hospital Study Period
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout the hospital study period (1 to 10 days post-randomization)
Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, Throughout Hospital Study Period
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL (Umpierrez et al. 2007; Moghissi et al. 2009; Umpierrez et al. 2009), even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), Throughout Hospital Study Period
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Number (Incidence) of Hypoglycemia and Severe Hypoglycemia Episodes, by Hospital Day
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Number of Hypoglycemia and Severe Hypoglycemia Episodes Adjusted for 30 Days (Rate), by Hospital Day
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.
Time frame: Day 1 up to day 10 of hospital study period
Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period
Treatment-emergent adverse event - any untoward medical occurrence that either occurred or worsened at any time after treatment baseline and which did not necessarily have a causal relationship with this treatment. A summary of adverse events is located in the Reported Adverse Event Module.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Percentage of Participants Requiring Intensive Care Unit Transfer
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Percentage of Participants With Deterioration of Renal Function Throughout the Hospital Study Period
Deterioration of renal function was defined by an increase in serum creatinine by \>0.5 milligrams per deciliter (mg/dL). Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Percentage of Participants With Documented Nosocomial Infections
Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
Number of Participants With Major Adverse Cardiovascular Events (MACE)
MACE was defined as the composite of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Due to low enrollment, this outcome measure was not analyzed.
Time frame: Throughout hospital study period (1 to 10 days post-randomization)
| Milestone | Sliding Scale Regular Insulin | Basal-bolus Therapy |
|---|---|---|
| Started | 9 | 7 |
| Completed | 6 | 4 |
| Not completed | 3 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Death | 1 | 0 |
Overall MPG is derived as the mean of plasma glucose (PG) readings from Day/Visit 1 to Day/Visit 10.
| milligrams per deciliter (mg/dL) | Sliding Scale Regular Insulin | Basal-bolus Therapy |
|---|---|---|
| Mean Plasma Glucose (MPG) Throughout Hospital Study Period | 167.6 ± 48.5 | 128.4 ± 22.4 |
Results are reported as the percentage of total number of capillary plasma glucose measurements within the range of 71 to 179 mg/dL for each treatment arm.
| percentage of capillary PG measurements | Sliding Scale Regular Insulin | Basal-bolus Therapy |
|---|---|---|
| Percentage of Capillary Plasma Glucose Measurements Within the Range of 71 to 179 mg/dL Throughout the Hospital Study Period | 81.4 | 84.3 |
The intent was to report results up to Day 10; however, due to low enrollment, mean and standard deviations are only reported up to Day 7.
| mg/dL | Sliding Scale Regular Insulin | Basal-bolus Therapy |
|---|---|---|
| Day 1 (n=6, n=6) | 178.1 ± 54.9 | 149.9 ± 17.2 |
| Day 2 (n=8, n=5) | 175.2 ± 57.9 | 124.0 ± 29.8 |
| Day 3 (n=6, n=3) | 151.0 ± 46.9 | 128.5 ± 28.5 |
| Day 4 (n=2, n=1) | 132.5 ± 2.12 | 96.3 ± NA |
| Day 5 (n=1, n=1) | 154.8 ± NA | 104.6 ± NA |
| Day 6 (n=1, n=1) | 138.0 ± NA | 111.0 ± NA |
| Day 7 (n=0, n=1) | NA ± NA | 108.0 ± NA |
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL (Umpierrez et al. 2007; Moghissi et al. 2009; Umpierrez et al. 2009), even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose.
| hypoglycemic episodes | Sliding Scale Regular Insulin | Basal-bolus Therapy |
|---|---|---|
| Hypoglycemic Episodes | 1 | 3 |
| Severe Hypoglycemic Episodes | 0 | 0 |
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Hypoglycemia was defined as any time a recorded capillary PG level is ≤70 mg/dL, even if it is not associated with signs or symptoms, or treatment consistent with current guidelines (ADA 2005; ADA 2010). Severe hypoglycemia was defined as an episode associated with a recorded capillary (or venous) PG \<40 mg/dL, even if it is not associated with need for assistance or neuroglycopenic symptoms (ADA 2005) or prompt recovery after oral carbohydrate, glucagon, or IV glucose. Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Treatment-emergent adverse event - any untoward medical occurrence that either occurred or worsened at any time after treatment baseline and which did not necessarily have a causal relationship with this treatment. A summary of adverse events is located in the Reported Adverse Event Module.
| participants | Sliding Scale Regular Insulin | Basal-bolus Therapy |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events Throughout Hospital Study Period | 1 | 2 |
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Deterioration of renal function was defined by an increase in serum creatinine by \>0.5 milligrams per deciliter (mg/dL). Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
MACE was defined as the composite of all-cause death, nonfatal myocardial infarction (MI), or nonfatal stroke. Due to low enrollment, this outcome measure was not analyzed.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sliding Scale Regular Insulin | — | 1/9 (11.1%) | 1/9 (11.1%) |
| Basal-bolus Therapy | — | 0/7 (0%) | 2/7 (28.6%) |
| Event | Sliding Scale Regular Insulin | Basal-bolus Therapy |
|---|---|---|
| Myocardial infarctionCardiac disorders | 1/9 | 0/7 |
| Event | Sliding Scale Regular Insulin | Basal-bolus Therapy |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/9 | 1/7 |
| High density lipoprotein decreasedInvestigations | 0/9 | 1/7 |
| Age Continuous(years) | Sliding Scale Regular Insulin | Basal-bolus Therapy | Total |
|---|---|---|---|
| Mean | 60.2 ± 16.8 | 51.4 ± 8.5 | 56.4 ± 14.1 |
| Sex: Female, Male(Participants) | Sliding Scale Regular Insulin | Basal-bolus Therapy | Total |
|---|---|---|---|
| Female | 5 | 2 | 7 |
| Male | 4 | 5 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Sliding Scale Regular Insulin | Basal-bolus Therapy | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 8 | 7 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sliding Scale Regular Insulin | Basal-bolus Therapy | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 2 | 7 |
| White | 4 | 5 | 9 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sliding Scale Regular Insulin | Basal-bolus Therapy | Total |
|---|---|---|---|
| United States | 9 | 7 | 16 |
The record gives a start of Mar 2011, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin Lispro · Insulin Glargine